

# Giovanni D Di Minno

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9209299/publications.pdf>

Version: 2024-02-01

212  
papers

7,574  
citations

44069

48  
h-index

69250

77  
g-index

217  
all docs

217  
docs citations

217  
times ranked

8257  
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring Plasma Fibrinogen to Predict Stroke and Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1368-1377.	2.4	287
2	Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. <i>American Journal of Medicine</i> , 1985, 79, 552-559.	1.5	228
3	Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). <i>Thrombosis and Haemostasis</i> , 2013, 109, 1170-1179.	3.4	188
4	International recommendations on the diagnosis and treatment of acquired hemophilia A. <i>Haematologica</i> , 2020, 105, 1791-1801.	3.5	182
5	Genetic susceptibility to pregnancy-related venous thromboembolism: Roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. <i>American Journal of Obstetrics and Gynecology</i> , 1998, 179, 1324-1328.	1.3	168
6	Insight into the nature of the CRPâ€“coronary event association using Mendelian randomization. <i>International Journal of Epidemiology</i> , 2006, 35, 922-931.	1.9	159
7	Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 141-147.	3.4	144
8	PAI-1 Plasma Levels in a General Population Without Clinical Evidence of Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 562-567.	2.4	140
9	Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 867-873.	2.4	137
10	Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 852-857.	3.4	137
11	Homocysteine, Coagulation, Platelet Function, and Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2000, Volume 26, 243-254.	2.7	131
12	Red Wine Consumption and Cardiovascular Health. <i>Molecules</i> , 2019, 24, 3626.	3.8	131
13	Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1297-1302.	3.8	129
14	The PAI-1 Gene Locus 4G/5G Polymorphism Is Associated With a Family History of Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 152-156.	2.4	128
15	Inherited Prothrombotic Conditions and Premature Ischemic Stroke. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1751-1756.	2.4	113
16	Hyperhomocysteinemia and Other Inherited Prothrombotic Conditions in Young Adults With a History of Ischemic Stroke. <i>Stroke</i> , 2002, 33, 51-56.	2.0	112
17	Carotid Intima-Media Thickness in Psoriatic Arthritis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 705-712.	2.4	111
18	Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. <i>Oncologist</i> , 2017, 22, 601-608.	3.7	108

#	ARTICLE	IF	CITATIONS
19	Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high responding inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1809-1815.	3.8	103
20	New Insights Into the Treatment of Glanzmann Thrombasthenia. <i>Transfusion Medicine Reviews</i> , 2016, 30, 92-99.	2.0	95
21	Preventing adverse obstetric outcomes in women with genetic thrombophilia. <i>Fertility and Sterility</i> , 2002, 78, 371-375.	1.0	90
22	Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. <i>Haemophilia</i> , 2012, 18, e173-87.	2.1	88
23	Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). <i>Haematologica</i> , 2013, 98, 538-544.	3.5	82
24	Plasma Folate, Vitamin B <sub>12</sub> , and Total Homocysteine and Homozygosity for the C677T Mutation of the 5,10-Methylene Tetrahydrofolate Reductase Gene in Patients with Alzheimer's Dementia. <i>Gerontology</i> , 2001, 47, 324-329.	2.8	81
25	The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1459-1466.	3.8	81
26	Prevalence of Apolipoprotein E Alleles in Healthy Subjects and Survivors of Ischemic Stroke. <i>Stroke</i> , 1998, 29, 399-403.	2.0	80
27	Inherited Thrombophilic Risk Factors and Venous Thromboembolism. <i>Chest</i> , 2000, 118, 1405-1411.	0.8	79
28	Anticardiolipin Antibodies in Patients With Liver Disease. <i>American Journal of Gastroenterology</i> , 1999, 94, 2983-2987.	0.4	78
29	Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. <i>Thrombosis Research</i> , 2015, 135, 923-932.	1.7	78
30	Homocysteine and arterial thrombosis: Challenge and opportunity. <i>Thrombosis and Haemostasis</i> , 2010, 103, 942-961.	3.4	77
31	Inherited Thrombophilia: Implications for Prevention and Treatment of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 683-694.	2.7	75
32	Perioperative handling of patients on antiplatelet therapy with need for surgery. <i>Internal and Emergency Medicine</i> , 2009, 4, 279-288.	2.0	74
33	Plasminogen Activator Inhibitor-1 (PAI-1) Antigen Plasma Levels in Subjects Attending a Metabolic Ward: Relation to Polymorphisms of PAI-1 and Angiotensin Converting Enzyme (ACE) Genes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2082-2087.	2.4	69
34	High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria. <i>Diabetologia</i> , 1997, 40, 1191-1196.	6.3	69
35	Deletion Polymorphism in the Angiotensin-Converting Enzyme Gene in Patients With a History of Ischemic Stroke. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 304-309.	2.4	68
36	Cost of care of haemophilia with inhibitors. <i>Haemophilia</i> , 2010, 16, e190-201.	2.1	66

#	ARTICLE	IF	CITATIONS
37	Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2250-2257.	2.4	65
38	Glanzmann's Thrombasthenia: Identification of 19 New Mutations in 30 Patients. <i>Thrombosis and Haemostasis</i> , 2002, 87, 1034-1042.	3.4	62
39	Magnetic resonance imaging and ultrasound evaluation of "healthy" joints in young subjects with severe haemophilia A. <i>Haemophilia</i> , 2013, 19, e167-73.	2.1	60
40	Glanzmann's thrombasthenia (defective platelet integrin $\alpha$ IIb $\beta$ 3): proposals for management between evidence and open issues. <i>Thrombosis and Haemostasis</i> , 2009, 102, 1157-1164.	3.4	57
41	High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. <i>World Journal of Gastroenterology</i> , 2010, 16, 6119.	3.3	57
42	EPCR Ser219Gly: Elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. <i>Atherosclerosis</i> , 2005, 183, 283-292.	0.8	56
43	Gender differences in left ventricular chamber and midwall systolic function in normotensive and hypertensive adults. <i>Journal of Hypertension</i> , 2003, 21, 1415-1423.	0.5	55
44	Oral Anticoagulant Drugs and the Risk of Osteoporosis: New Anticoagulants Better than Old?. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 382-388.	2.7	54
45	Arthropathy in Patients with Moderate Hemophilia A: A Systematic Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 723-731.	2.7	53
46	The international prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. <i>Haematologica</i> , 2015, 100, 1038-44.	3.5	53
47	The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2322-2329.	3.8	52
48	Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 15812-15817.	7.1	52
49	C-Reactive Protein in Offspring Is Associated With the Occurrence of Myocardial Infarction in First-Degree Relatives. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 198-203.	2.4	49
50	Predictors of Early Minimal Disease Activity in Patients with Psoriatic Arthritis Treated with Tumor Necrosis Factor- $\alpha$ Blockers. <i>Journal of Rheumatology</i> , 2012, 39, 568-573.	2.0	48
51	Replacement therapy for bleeding episodes in factor VII deficiency. <i>Thrombosis and Haemostasis</i> , 2013, 109, 238-247.	3.4	48
52	Association Between the Metabolic Syndrome, Its Individual Components, and Unprovoked Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2478-2485.	2.4	48
53	Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. <i>Blood Transfusion</i> , 2015, 13, 498-513.	0.4	48
54	Haemophilia A: molecular insights. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 450-61.	2.3	47

#	ARTICLE	IF	CITATIONS
55	Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2350.	4.1	47
56	Cardiovascular Risk in Rheumatic Patients: The Link between Inflammation and Atherothrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 497-505.	2.7	46
57	Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: A Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 267-274.	2.7	44
58	Italian intersociety consensus on DOAC use in internal medicine. <i>Internal and Emergency Medicine</i> , 2017, 12, 387-406.	2.0	44
59	Uncomplicated type 1 diabetes and preclinical left ventricular myocardial dysfunction: Insights from echocardiography and exercise cardiac performance evaluation. <i>Diabetes Research and Clinical Practice</i> , 2008, 79, 262-268.	2.8	43
60	The international prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes in non-surgical bleeding episodes in Glanzmann thrombasthenia patients. <i>Haematologica</i> , 2015, 100, 1031-7.	3.5	43
61	Fibrinogen Naples I (B <sup>12</sup> A68T) Nonsubstrate Thrombin-Binding Capacities. <i>Thrombosis Research</i> , 2001, 103, 63-73.	1.7	42
62	Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1122-1128.	3.4	42
63	Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis. <i>European Journal of Clinical Investigation</i> , 2007, 37, 48-53.	3.4	42
64	Homozygous C677T Mutation of the 5,10 Methylene tetrahydrofolate Reductase Gene and Hyperhomocysteinemia in Italian Patients With a History of Early-Onset Ischemic Stroke. <i>Stroke</i> , 1998, 29, 869-871.	2.0	40
65	The Infectious Burden in Atherothrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 515-523.	2.7	39
66	Ensuring medication adherence with direct oral anticoagulant drugs. <i>Thrombosis Research</i> , 2014, 133, 699-704.	1.7	39
67	IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. <i>Journal of Clinical Investigation</i> , 2015, 125, 3766-3781.	8.2	39
68	Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. <i>American Journal of Cardiology</i> , 1999, 83, 1196-1200.	1.6	38
69	Hepatic Steatosis and Disease Activity in Subjects with Psoriatic Arthritis Receiving Tumor Necrosis Factor- $\alpha$ Blockers. <i>Journal of Rheumatology</i> , 2012, 39, 1042-1046.	2.0	38
70	Endothelin Abnormalities in Patients With Pulmonary Embolism. <i>Chest</i> , 1997, 111, 544-549.	0.8	37
71	Glanzmann's Thrombasthenia Treatment: A Prospective Observational Registry on the Use of Recombinant Human Activated Factor VII and Other Hemostatic Agents. <i>Seminars in Hematology</i> , 2006, 43, S33-S36.	3.4	37
72	Increased troponin I predicts in-hospital occurrence of hemodynamic instability in patients with sub-massive or non-massive pulmonary embolism independent to clinical, echocardiographic and laboratory information. <i>International Journal of Cardiology</i> , 2008, 124, 351-357.	1.7	37

#	ARTICLE	IF	CITATIONS
73	Diabetes, vascular complications and antiplatelet therapy: open problems. <i>Acta Diabetologica</i> , 2009, 46, 253-261.	2.5	37
74	Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention. <i>Annals of Medicine</i> , 2011, 43, 531-544.	3.8	37
75	Increased prostacyclin-like activity in vascular tissues from rats on long-term treatment with an oestrogen-progestagen combination. <i>Thrombosis Research</i> , 1979, 14, 793-797.	1.7	34
76	Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. <i>Blood Reviews</i> , 2016, 30, 35-48.	5.7	34
77	Platelet Reactivity and Disease Activity in Subjects with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 334-336.	2.0	32
78	Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. <i>Internal and Emergency Medicine</i> , 2012, 7, 9-13.	2.0	32
79	Aspirin Resistance, Platelet Turnover, and Diabetic Angiopathy: A 2011 Update. <i>Thrombosis Research</i> , 2012, 129, 341-344.	1.7	30
80	Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. <i>Journal of Immunology Research</i> , 2017, 2017, 1-13.	2.2	29
81	Efficacy and safety of prophylaxis with once-weekly BAY 794980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. <i>Thrombosis and Haemostasis</i> , 2012, 108, 913-922.	3.4	28
82	A prospective study on survival in cancer patients with and without venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2014, 9, 559-67.	2.0	27
83	Venous Thromboembolism in COVID-19 Compared to Non-COVID-19 Cohorts: A Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4925.	2.4	27
84	Persistent Impairment of Platelet Aggregation following Cessation of a Short-course Dietary Supplementation of Moderate Amounts of N-3 Fatty Acid Ethyl Esters. <i>Thrombosis and Haemostasis</i> , 1999, 82, 128-133.	3.4	26
85	Exploring newer cardioprotective strategies: Ï-3 fatty acids in perspective. <i>Thrombosis and Haemostasis</i> , 2010, 104, 664-680.	3.4	26
86	Lower birth-weight in neonates of mothers carrying factor V G1691A and factor II A(20210) mutations. <i>Haematologica</i> , 2002, 87, 177-81.	3.5	26
87	Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives. <i>Thrombosis Research</i> , 2015, 136, 1074-1081.	1.7	25
88	Drugs affecting plasma fibrinogen levels. <i>Cardiovascular Drugs and Therapy</i> , 1992, 6, 25-27.	2.6	24
89	Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research. <i>Blood Reviews</i> , 2015, 29, 335-343.	5.7	24
90	Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine. <i>Blood Reviews</i> , 2020, 39, 100618.	5.7	24

#	ARTICLE	IF	CITATIONS
91	Mesoglycan: Clinical Evidences for Use in Vascular Diseases. <i>International Journal of Vascular Medicine</i> , 2010, 2010, 1-8.	1.0	23
92	Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2017, 12, 1291-1305.	2.0	23
93	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and Siset. <i>Blood Transfusion</i> , 2020, 18, 143-151.	0.4	22
94	Spontaneous Muscle Hematoma in Patients with COVID-19: A Systematic Literature Review with Description of an Additional Case Series. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 100-108.	2.7	21
95	The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. <i>Blood Transfusion</i> , 2016, 14, 255-61.	0.4	21
96	The Causal Role of Salt Depletion in Acute Renal Failure Due to Captopril in Hypertensive Patients with a Single Functioning Kidney and Renal Artery Stenosis. <i>Renal Failure</i> , 1987, 10, 9-20.	2.1	20
97	Left Ventricular Chamber and Myocardial Systolic Function Reserve in Patients with Type 1 Diabetes Mellitus: Insight from Traditional and Doppler Tissue Imaging Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 848-856.	2.8	20
98	Molecular analysis and genotype-phenotype correlation in patients with antithrombin deficiency from Southern Italy. <i>Thrombosis and Haemostasis</i> , 2012, 107, 673-680.	3.4	20
99	Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. <i>Haematologica</i> , 2013, 98, 1495-1498.	3.5	20
100	Denaturing HPLC Procedure for Factor IX Gene Scanning. <i>Clinical Chemistry</i> , 2003, 49, 815-818.	3.2	19
101	Acquired Haemophilia A in the Elderly: Case Reports. <i>Current Gerontology and Geriatrics Research</i> , 2010, 2010, 1-5.	1.6	19
102	Aspirin resistance and platelet turnover: A 25-year old issue. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 542-545.	2.6	19
103	Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 2633-2641.	1.3	19
104	Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 468-477.	2.7	19
105	Haemophilia B: From Molecular Diagnosis to Gene Therapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 445-51.	2.3	18
106	Aspirin resistance and diabetic angiopathy: back to the future. <i>Thrombosis Research</i> , 2004, 113, 97-99.	1.7	18
107	Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?. <i>Annals of Hematology</i> , 2017, 96, 1253-1270.	1.8	18
108	Reduced in vivo oxidative stress following 5-methyltetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methylenetetrahydrofolate reductase genotype. <i>British Journal of Haematology</i> , 2005, 131, 100-108.	2.5	17



#	ARTICLE	IF	CITATIONS
109	Left ventricular diastolic abnormalities other than valvular heart disease in antiphospholipid syndrome: An echocardiographic study. <i>International Journal of Cardiology</i> , 2018, 271, 366-370.	1.7	17
110	Low Rate of Intrahospital Deep Venous Thrombosis in Acutely Ill Medical Patients: Results From the AURELIO Study. <i>Mayo Clinic Proceedings</i> , 2019, 94, 37-43.	3.0	17
111	Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) project. <i>Haemophilia</i> , 2019, 25, 656-667.	2.1	16
112	From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation. <i>Blood Reviews</i> , 2020, 39, 100613.	5.7	16
113	Clinical use of factor VIII and factor IX concentrates. <i>Blood Transfusion</i> , 2013, 11 Suppl 4, s55-63.	0.4	16
114	Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution?. <i>Haemophilia</i> , 2013, 19, 18-23.	2.1	15
115	Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. <i>Annals of Medicine</i> , 2014, 46, 475-489.	3.8	15
116	Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey. <i>Haemophilia</i> , 2014, 20, e128-35.	2.1	15
117	DIPYRIDAMOLE AND PLATELET FUNCTION. <i>Lancet, The</i> , 1978, 312, 1257-1259.	13.7	14
118	Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 199-201.	1.0	14
119	Protein C and protein S changes in GH-deficient adults on r-HGH replacement therapy. <i>Thrombosis Research</i> , 2010, 126, e434-e438.	1.7	14
120	Genotype-independent in vivo oxidative stress following a methionine loading test: Maximal platelet activation in subjects with early-onset thrombosis. <i>Thrombosis Research</i> , 2011, 128, e43-e48.	1.7	14
121	Filling the gap between science & clinical practice: Prevention of stroke recurrence. <i>Thrombosis Research</i> , 2012, 129, 3-8.	1.7	14
122	TNF- $\alpha$ blockers and carotid intima-media thickness: an emerging issue in the treatment of psoriatic arthritis. <i>Internal and Emergency Medicine</i> , 2012, 7, 97-98.	2.0	14
123	Laboratory tests during direct oral anticoagulant treatment? No. <i>Internal and Emergency Medicine</i> , 2013, 8, 367-370.	2.0	14
124	Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine. <i>Haematologica</i> , 2017, 102, 411-418.	3.5	14
125	Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A. <i>Haemophilia</i> , 2021, 27, e422-e433.	2.1	14
126	HELLP syndrome and its relation with the antiphospholipid syndrome. <i>Blood Transfusion</i> , 2014, 12, 114-8.	0.4	14



#	ARTICLE	IF	CITATIONS
127	Glanzmann's thrombasthenia: identification of 19 new mutations in 30 patients. <i>Thrombosis and Haemostasis</i> , 2002, 87, 1034-42.	3.4	14
128	Acute coronary syndrome and severe haemophilia: An unusual association with challenging treatment. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1270-1272.	3.4	13
129	Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect. <i>Thrombosis and Haemostasis</i> , 2014, 112, 424-425.	3.4	13
130	Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. <i>Internal and Emergency Medicine</i> , 2019, 14, 21-38.	2.0	13
131	Polyunsaturated fatty acids, thrombosis and vascular disease. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002, 32, 361-364.	0.3	12
132	Pregnancy in a woman with a history of Budd-Chiari syndrome treated by porto-systemic shunt, protein C deficiency and bicornuate uterus. <i>Thrombosis and Haemostasis</i> , 2006, 95, 1033-1034.	3.4	12
133	A new method for determination of plasma homocystine by isotope dilution and electrospray tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 842, 64-69.	2.3	12
134	Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving Threats. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 779-793.	2.7	12
135	Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis. <i>Thrombosis Research</i> , 2014, 134, 264-267.	1.7	12
136	Blood Group O Protects against Inhibitor Development in Severe Hemophilia A Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 069-074.	2.7	12
137	Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2017, 99, 306-314.	2.2	12
138	Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE). <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 551-560.	2.7	12
139	Attempting to remedy sub-optimal medication adherence in haemophilia: The rationale for repeated ultrasound visualisations of the patient's joint status. <i>Blood Reviews</i> , 2019, 33, 106-116.	5.7	12
140	The International Prospective Glanzmann Thrombasthenia Registry: Pediatric Treatment and Outcomes. <i>TH Open</i> , 2019, 03, e286-e294.	1.4	12
141	Risk factors and recurrent thrombotic episodes in patients with cerebral venous thrombosis. <i>Blood Transfusion</i> , 2014, 12 Suppl 1, s337-42.	0.4	12
142	Influence of cardiovascular risk factors on relation between angiotensin converting enzyme-gene polymorphism and blood pressure in arterial hypertension. <i>Journal of Hypertension</i> , 1998, 16, 985-991.	0.5	11
143	Improving the use of direct oral anticoagulants in atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2013, 24, 288-294.	2.2	11
144	&lt;p&gt;Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 233-240.	1.8	11

#	ARTICLE	IF	CITATIONS
145	Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. <i>Current Vascular Pharmacology</i> , 2021, 19, 542-555.	1.7	11
146	A Fast and Accurate Method for Genotyping the Angiotensin-Converting Enzyme I/D Polymorphism. <i>Circulation</i> , 1998, 97, 1213-1214.	1.6	10
147	Cardiovascular events in patients with antiphospholipid antibodies: Strategies of prevention. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 217-223.	2.6	10
148	Novel oral anticoagulants in atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 512-519.	1.5	10
149	Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders. <i>Blood Reviews</i> , 2015, 29, S26-S33.	5.7	10
150	Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. <i>American Journal of Hematology</i> , 2017, 92, 646-652.	4.1	10
151	Lack of change in insulin levels as a biological marker of PAI-1 lowering in GH-deficient adults on r-HGH replacement therapy. <i>Thrombosis Research</i> , 2009, 124, 711-713.	1.7	9
152	New Anti-Thrombotic Drugs for Stroke Prevention. <i>Current Vascular Pharmacology</i> , 2011, 9, 723-732.	1.7	9
153	Alcohol Dosing and the Heart: Updating Clinical Evidence. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 875-884.	2.7	9
154	Knowledge of cardiovascular risk factors and awareness of non-pharmacological approach for risk prevention in young survivors of acute myocardial infarction. The cardiovascular risk prevention project "Help Your Heart Stay Young". <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 468-472.	2.6	8
155	Prenatal diagnosis of haemophilia: our experience of 44 cases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2233-2238.	2.3	8
156	Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study. <i>Blood Transfusion</i> , 2020, 18, 152-158.	0.4	8
157	Pain assessment and management in Italian Haemophilia Centres. <i>Blood Transfusion</i> , 2021, 19, 335-342.	0.4	8
158	Newer agents for coronary thrombolysis. Perspectives from clinical studies. <i>Pharmacological Research</i> , 1989, 21, 153-161.	7.1	7
159	Urinary excretion of iPF2 $\pm$ -III predicts the risk of future thrombotic events. A 10-year follow-up. <i>Thrombosis Research</i> , 2012, 129, 208-211.	1.7	7
160	Methylation Reactions, the Redox Balance and Atherothrombosis: The Search for a Link with Hydrogen Sulfide. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 423-432.	2.7	7
161	Thromboprophylaxis with Low-Molecular-Weight Heparins: An Assessment of the Methodological Quality of Studies. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 113-132.	2.7	7
162	The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies. <i>Blood Reviews</i> , 2021, 46, 100737.	5.7	7

#	ARTICLE	IF	CITATIONS
163	Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement. <i>Blood Reviews</i> , 2022, 51, 100885.	5.7	7
164	Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors. <i>Haemophilia</i> , 2022, 28, 55-64.	2.1	7
165	Impact of prothrombotic mutations and family history on the occurrence of intra-uterine fetal deaths. <i>Haematologica</i> , 2002, 87, 1118-9.	3.5	7
166	Fibrinolytic, platelet and monocyte variables in homozygous familial hypercholesterolemia. The effect of a regular plasma cholesterol removal by LDL-apheresis. <i>Fibrinolysis</i> , 1993, 7, 63-64.	0.5	6
167	The Use of Frozen-Thawed Platelet-Derived Phospholipids as a Confirmatory Test for the Diagnosis of Lupus Anticoagulants. Comparison with Two Commercial Confirmatory System Tests. <i>Thrombosis Research</i> , 1999, 94, 373-380.	1.7	6
168	The role of the metabolic syndrome in patients with provoked venous thromboembolic events. <i>Thrombosis and Haemostasis</i> , 2013, 109, 759-761.	3.4	6
169	The risk of gastrointestinal bleeding in patients receiving dabigatran etexilate: a systematic review and meta-analysis of the literature. <i>Annals of Medicine</i> , 2017, 49, 329-342.	3.8	6
170	Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients. <i>Internal and Emergency Medicine</i> , 2017, 12, 425-435.	2.0	6
171	Glanzmann's thrombasthenia: strategies for identification and management. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 641-653.	0.8	6
172	Searching for the thrombogenic mechanism(s) of fibrinogen. <i>Thrombosis Research</i> , 1990, 57, 61-67.	1.7	5
173	Identifying human platelet glycoproteins IIb and IIIa by capillary electrophoresis. <i>Electrophoresis</i> , 1998, 19, 1468-1474.	2.4	5
174	Adverse outcome in women with thrombophilia and bilateral uterine artery notches. <i>Fertility and Sterility</i> , 2006, 86, 726-727.	1.0	5
175	Assessing joint involvement in haemophilia by clinical rheumatologic scores. A pilot study on similarities with subjects with psoriatic arthritis. <i>Clinical Rheumatology</i> , 2011, 30, 915-919.	2.2	5
176	Noninvasive Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C (and Congenital) Tj ETQq0 0 0 rgBT /Qverlock 10 Tf 50 22	2.7	5
177	Anticoagulant Therapy in Oncologic Patients Undergoing Venous Stenting for Superior Vena Cava Syndrome and Other Interventional Procedures. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 1401-1402.	2.0	5
178	Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis. <i>Internal and Emergency Medicine</i> , 2019, 14, 447-449.	2.0	5
179	Genetic Variants Associated with Non-Alcoholic Fatty Liver Disease Do Not Associate with Measures of Sub-Clinical Atherosclerosis: Results from the IMPROVE Study. <i>Genes</i> , 2020, 11, 1243.	2.4	5
180	Acquired Factor V Inhibitor after Coronavirus Disease 2019 (COVID-19). <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 124-126.	2.7	5

#	ARTICLE	IF	CITATIONS
181	Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates. <i>Blood Transfusion</i> , 2013, 11 Suppl 4, s101-9.	0.4	5
182	RASopathies and hemostatic abnormalities: key role of platelet dysfunction. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 499.	2.7	5
183	Right-to-left shunt, atrial septal aneurysm and thrombophilia in patients with cryptogenic stroke or TIA vs. those with venous thrombo-embolism. <i>International Journal of Cardiology</i> , 2008, 130, 99-102.	1.7	4
184	The Challenge of Diagnosing Pulmonary Embolism in Children, Pregnant Women, and Elderly Patients: A Descriptive Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 908-917.	2.7	4
185	Acquired Hemophilia A successfully treated with rituximab. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015024.	1.3	4
186	Blood stains of the Turin Shroud 2015: beyond personal hopes and limitations of techniques. <i>Internal and Emergency Medicine</i> , 2016, 11, 507-516.	2.0	4
187	Perspective “The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021. <i>Blood Reviews</i> , 2021, 50, 100849.	5.7	4
188	Current and evolving features in the clinical management of haemophilia. <i>Blood Transfusion</i> , 2014, 12 Suppl 3, s554-62.	0.4	4
189	Increased PGI2 activity in venous tissues from rats on oral contraceptives is not prevented by heparin administration before vessel isolation. <i>Thrombosis Research</i> , 1980, 18, 895-896.	1.7	3
190	Arachidonic acid induces human platelet-fibrin retraction: The role of platelet cyclic endoperoxides. <i>Thrombosis Research</i> , 1982, 25, 299-306.	1.7	3
191	Idiopathic Budd-Chiari syndrome in a patient with homozygous Factor V Leiden and heterozygous Factor II G20210A mutations. <i>Thrombosis Research</i> , 2000, 100, 567-568.	1.7	3
192	Human genome, environment and medical practice. <i>Internal and Emergency Medicine</i> , 2013, 8, 645-649.	2.0	3
193	Cytomegalovirus-Associated Splanchnic Vein Thrombosis in Immunocompetent Patients: Two Case Reports and Literature Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 298-303.	2.7	3
194	Convalescent plasma for administration of passive antibodies against viral agents. <i>Haematologica</i> , 2020, 105, 2710-2715.	3.5	3
195	A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?. <i>Blood Transfusion</i> , 2011, 9 Suppl 2, s14-20.	0.4	3
196	Management of bleeding in acquired haemophilia A with recombinant activated factor VII: does one size fit all? A report of four cases. <i>Blood Transfusion</i> , 2015, 13, 328-32.	0.4	3
197	Plasmatic and vascular factors of the hemostatic system in rats receiving an estrogen-progestogen combination. <i>Contraception</i> , 1980, 22, 249-257.	1.5	2
198	Hemostatic variables and ischemic cardiovascular disease: Do we need a concerted effort for more profitable future clinical investigations?. <i>Cardiovascular Drugs and Therapy</i> , 1997, 10, 743-749.	2.6	2

#	ARTICLE	IF	CITATIONS
199	Coexistence of Thrombophilic Gene Polymorphisms Among 559 Unrelated Consecutive Patients With a History of Thrombosis. <i>Thrombosis Research</i> , 2001, 101, 317-319.	1.7	2
200	Preclinical and prognostically relevant cardiovascular disease burden in systemic lupus erythematosus with low clinical damage index. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, e23-e25.	2.6	2
201	Upper tract urothelial cell carcinoma presenting as fever of unknown origin and acid-sterile pyuria. <i>Internal and Emergency Medicine</i> , 2012, 7, 117-118.	2.0	2
202	Commentary on: Borrini M, Garlaschelli L. A BPA Approach to the Shroud of Turin. <i>J Forensic Sci</i> 2019;64(1):137-43. <i>Journal of Forensic Sciences</i> , 2019, 64, 325-326.	1.6	2
203	Definition of an organisational model for the prevention and reduction of health and social impacts of inherited bleeding disorders. <i>Blood Transfusion</i> , 2014, 12 Suppl 3, s582-8.	0.4	2
204	Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with) Tj ETQq0 0 0 rgBT /Qverlock, 10 Tf 50 5	0.4	2
205	Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving Threats. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 973-973.	2.7	1
206	Laboratory tests during direct oral anticoagulant treatment? Authors' reply. <i>Internal and Emergency Medicine</i> , 2015, 10, 533-534.	2.0	1
207	Effects of PGE <sub>2</sub> Infusion on Renal Function in Normal Man before and after Angiotensin II Inhibition by Captopril. <i>Kidney and Blood Pressure Research</i> , 1987, 10, 289-296.	2.0	0
208	Severe pancytopenia and intrahepatic cholestasis in a patient with a history of Hodgkin's disease. <i>European Journal of Internal Medicine</i> , 2001, 12, 515-517.	2.2	0
209	Prophylaxis of venous thromboembolism in elderly patients with multi-morbidity: the REPOSI data. <i>Internal and Emergency Medicine</i> , 2015, 10, 251-252.	2.0	0
210	Replacement Therapy for Surgery in FVII Deficiency: The Ster Experience Concerning 63 Interventions. <i>Blood</i> , 2009, 114, 1290-1290.	1.4	0
211	Aspirin as an antithrombotic agent. , 1989, 33, 43-62.		0
212	A survey on the views and attitudes of Italian physicians regarding the prophylaxis and treatment of venous thromboembolism. <i>Minerva Medica</i> , 2020, 111, 370-372.	0.9	0